Catalyst
Slingshot members are tracking this event:
In the second half of 2017, Halozyme Therapeutics (HALO) preparing to commence Phase 1 trial on combination of PEG PH20 and atezolizumab in treating gallbladder tumors
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| HALO | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jul 13, 2017
Occurred Source:
http://www.halozyme.com/investors/news-releases/news-release-details/2017/Initiation-Of-Clinical-Trial-Collaboration-Evaluating-Halozymes-PEGPH20-In-Combination-With-Anti-PDL1-Immunotherapy/default.aspx
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 1, Gallbladder Tumors, Pegph20, Ate Zo Lizumab
